Investors
Featured Press Release
WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference as
See More
Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income * was $4.10 per basic and $4.04 per diluted share Q1 2022 total revenue was $115.9 million, up from $41.2 million in Q1 2021 Achieved sales of $34.3 million of vasopressin, with prior four weeks
See More
WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens.
See More
Upcoming Events & Presentations
6/9/22 at 9:40 AM EDT